More Information About Alpidem

Alpidem
Systematic (IUPAC) name
2-[3-chloro-8-(4-chlorophenyl)-1,7-diazabicyclo[4.3.0] nona-2,4,6,8-tetraen-9-yl]-N,N-dipropyl-acetamide
Identifiers
CAS number	82626-01-5
ATC code	?
PubChem	54897
Chemical data
Formula	C21H23Cl2N3O
Mol. mass	404.332 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	Oral

Alpidem (Ananxyl) is an anxiolytic drug from the imidazopyridine family, related to the more well known sleeping medication zolpidem. Unlike zolpidem however, alpidem does not produce sedative effects at normal doses, and is instead used specifically for the treatment of anxiety.^[1][2]

Alpidem is a fairly recently introduced drug, and is not widely used. Alpidem acts selectively on the α3 receptor subtype and to a lesser extent at the α1 subtype (Kd of 0.33nM and 1.67nM respectively), of the benzodiazepine receptor.^[3][4] However the chemical structure of alpidem is not related to that of the benzodiazepines, and alpidem is thus sometimes referred to as a nonbenzodiazepine.^[5]

Indications

Alpidem is generally prescribed to patients with moderate to severe anxiety.^[6] Most of these patients have exhibited either sensitivity or resistance to benzodiazepine therapy, and therefore switched to a non-benzodiazepine medication due to the reduced incidence of side effects relative to benzodiazepine drugs.^[7][8] Alpidem produces little or no sedative or hypnotic action at normal doses but may produce sedation when used at a high dose, and only has anticonvulsant actions at much higher doses than those used clinically for the treatment of anxiety.^[9]

Dangers

Alpidem was withdrawn from the market in most of the world following reports of severe liver damage caused by Ananxyl,^[10][11] although other brands of alpidem may still be on sale in some countries.

See also

• Zolpidem
• Anxiolytic
• Benzodiazepine (receptor)
• Imidazopyridines

References